On October 13, 2009
Well Isn’t That Special: Overall Survival Still Oncology Gold Standard
There’s a world of difference between thinking your kid is the smartest in class and selling the principal on the idea, as cancer drug makers are learning when trying to sell the FDA on progression-free survival as a primary endpoint.
0 Comments